BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia
Phase 4
Completed
- Conditions
- ContraceptionMenorrhagia
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 204
- Registration Number
- NCT00393198
Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II
Phase 4
Completed
- Conditions
- Male Erectile DysfunctionSexual Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 352
- Registration Number
- NCT00377793
Dose Escalation Study of SH U04722 in Solid Tumors
Phase 1
Terminated
- Conditions
- Tumors
- Interventions
- Drug: SH U04722
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00375453
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
Phase 3
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-08-30
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT00370071
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 221
- Registration Number
- NCT00367276
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
Phase 3
Completed
- Conditions
- PreventionVenous Thromboembolism
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2531
- Registration Number
- NCT00361894
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
Phase 3
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3148
- Registration Number
- NCT00362232
Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
Phase 3
Completed
- Conditions
- Menorrhagia
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00360490
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Small Cell
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00359359
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
Phase 3
Completed
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Estradiol/DRSP (Angeliq, BAY86-4891)Drug: Placebo
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 249
- Registration Number
- NCT00356447
© Copyright 2025. All Rights Reserved by MedPath